Prevention of gastric cancer by Helicobacter pylori eradication

Digestive Diseases

Volumn 22, Issue 4, 2004, Pages 313-319

  Leodolter, A ^a   Naumann, M ^a   Malfertheiner, P ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Gastric cancer; Helicobacter pylori; Prevention of gastric cancer

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROSTAGLANDIN E2; ANTIINFECTIVE AGENT;

APOPTOSIS; CANCER PREVENTION; CANCER REGRESSION; CANCER RISK; CELL CYCLE; CELL PROLIFERATION; CLINICAL OBSERVATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; EPITHELIUM CELL; ERADICATION THERAPY; GASTRITIS; HEALING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; MOLECULAR MECHANICS; MUTATION; NONHUMAN; PRECANCER; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH EPITHELIUM; STOMACH LESION; STOMACH MUCOSA; STOMACH TUMOR; CHRONIC DISEASE; MICROBIOLOGY; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; DISEASE PROGRESSION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 21844475692     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083592     Document Type: Review

References (78)

1. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997:349:1498-1504.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Schistosomes, liver flukes and Helicobacter pylori, Lyon, June 7-14, 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241:1-241.
3. Ekstrom AM, Held M, Hansson LE, Engstrand L, Nyren O: Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001;121:784-791.
4. Helicobacter and Cancer Collaborative Group: Gastric cancer and Helicobacter pylori: A combined analysis of 12 case-control studies nested within prospective cohorts. Gut 2001;49:347-353.
5. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D: Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004;159:252-258.
6. Ohata H, Kitauchi S, Yoshimura N, et al: Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-143.
7. Correa P: Human gastric carcinogenesis: A multistep and multifactorial process. First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-6740.
8. Sipponen P, Marshall BJ: Gastritis and gastric cancer. Western countries. Gastroenterol Clin North Am 2000;29:579-592.
9. Meining A, Bayerdorffer E, Muller P, et al: Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch 1998;432:311-314.
10. Huang JQ, Sridhar S, Chen Y, Hunt RH: Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-1179.
11. Blaser MJ, Perez-Perez GI, Kleanthous H, et al: Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55:2111-2115.
12. Kuipers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ: Helicobacter pylori and atrophic gastritis: Importance of the cagA status. J Natl Cancer Inst 1995;87:1777-1780.
13. Webb PM, Crabtree JE, Forman D: Gastric cancer, cytotoxin-associated gene A-positive Helicobacter pylori, and serum pepsinogens: An international study. The Eurogst Study Group. Gastroenterology 1999;116:269-276.
14. El-Omar EM, Carrington M, Chow WH, et al: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
15. Machado JC, Pharoah P, Sousa S, et al: Interleukin-1B and interleukin-1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001;121:823-829.
16. Peek RM Jr, Moss SF, Tham KT, et al: Helicobacter pylori cagA+ strains and dissociation of gastric epithelial cell proliferation from apoptosis. J Natl Cancer Inst 1997;89:863-868.
17. Lynch DA, Mapstone NP, Clarke AM, et al: Correlation between epithelial cell proliferation and histological grading in gastric mucosa. J Clin Pathol 1999;52:367-371.
18. Moss SF, Sordillo EM, Abdalla AM, et al: Increased gastric epithelial cell apoptosis associated with colonization with cagA + Helicobacter pylori strains. Cancer Res 2001;61:1406-1411.
19. Lynch DA, Mapstone NP, Clarke AM, et al: Cell proliferation in Helicobacter pylori associated gastritis and the effect of eradication therapy. Gut 1995;36:346-350.
20. Cahill RJ, Kilgallen C, Beattie S, Hamilton H, O'Morain C: Gastric epithelial cell kinetics in the progression from normal mucosa to gastric carcinoma. Gut 1996;38:177-181.
21. Panella C, Ierardi E, Polimeno L, et al: Proliferative activity of gastric epithelium in progressive stages of Helicobacter pylori infection. Dig Dis Sci 1996;41:1132-1138.
22. Fraser AG, Sim R, Sankey EA, Dhillon AP, Pounder RE: Effect of eradication of Helicobacter pylori on gastric epithelial cell proliferation. Aliment Pharmacol Ther 1994;8:167-173.
23. Cahill RJ, Xia H, Kilgallen C, Beattie S, Hamilton H, O'Morain C: Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation. Dig Dis Sci 1995;40:1627-1631.
24. Leung WK, To KF, Chan FK, Lee TL, Chung SC, Sung JJ: Interaction of Helicobacter pylori eradication and non-steroidal anti-inflammatory drugs on gastric epithelial apoptosis and proliferation: Implications on ulcerogenesis. Aliment Pharmacol Ther 2000;14:879-885.
25. Suerbaum S, Smith JM, Bapumia K, et al: Free recombination within Helicobacter pylori. Proc Natl Acad Sci USA 1998;95:12619-12624.
26. Censini S, Lange C, Xiang Z, et al: cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 1996;93:14648-14653.
27. Akopyants NS, Clifton SW, Kersulyte D, et al: Analyses of the cag pathogenicity island of Helicobacter pylori. Mol Microbiol 1998;28:37-53.
28. Naumann M: Host cell signaling in Helicobacter pylori infection. Int J Med Microbiol 2001;291:299-305.
29. Crabtree JE, Farmery SM, Lindley IJ, Figura N, Peichl P, Tompkins DS: CagA/cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines. J Clin Pathol 1994;47:945-950.
30. Sharma SA, Tummuru MK, Miller GG, Blaser MJ: Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro. Infect Immun 1995;63:1681-1687.
31. Foryst-Ludwig A, Naumann M: p21-activated kinase 1 activates the NF-κB-inducing kinase-IκB kinases NF-κB pathway and proinflammatory cytokines in Helicobacter pylori infection. J Biol Chem 2000;275:39779-39785.
32. Naumann M, Wessler S, Bartsch C, et al: Activation of activator protein 1 and stress response kinases in epithelial cells colonized by Helicobacter pylori encoding the cag pathogenicity island. J Biol Chem 1999;274:31655-31662.
33. Viala J, Chaput C, Boneca IG, et al: Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 2004;5:1166-1174.
34. Naumann M, Crabtree JE: Helicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis. Trends Microbiol 2004;12:29-36.
35. Segal ED, Cha J, Lo J, Falkow S, Tompkins LS: Altered states: Involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc Natl Acad Sci USA 1999;96:14559-14564.
36. Asahi M, Azuma T, Ito S, et al: Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. J Exp Med 2000;191:593-602.
37. Backert S, Ziska E, Brinkmann V, et al: Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus. Cell Microbiol 2000;2:155-164.
38. Odenbreit S, Puls J, Sedlmaier B, Gerland E, Fischer W, Haas R: Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 2000;287:1497-1500.
39. Stein M, Rappuoli R, Covacci A: Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci USA 2000;97:1263-1268.
40. Barnard JA, Beauchamp RD, Russell WE, Dubois RN, Coffey RJ: Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology 1995;108:564-580.
41. Keates S, Sougioultzis S, Keates AC, et al: cag+ Helicobacter pylori induce transactivation of the epidermal growth factor receptor in AGS gastric epithelial cells. J Biol Chem 2001;276:48127-48134.
42. Wallasch C, Crabtree JE, Bevec D, Robinson PA, Wagner H, Ullrich A: Helicobacter pylori-stimulated EGF receptor transactivation requires metalloprotease cleavage of HB-EGF. Biochem Biophys Res Commun 2002;295:695-701.
43. Wong BC, Wang WP, So WH, et al: Epidermal growth factor and its receptor in chronic active gastritis and gastroduodenal ulcer before and after Helicobacter pylori eradication. Aliment Pharmacol Ther 2001;15:1459-1465.
44. Churin Y, Al Ghoul L, Kepp O, Meyer TF, Birchmeier W, Naumann M: Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol 2003;161:249-255.
45. Cook PW, Pittelkow MR, Keeble WW, Graves-Deal R, Coffey RJ Jr, Shipley GD: Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res 1992;52:3224-3227.
46. Cox JM, Clayton CL, Tomita T, Wallace DM, Robinson PA, Crabtree JE: cDNA array analysis of cag pathogenicity island-associated Helicobacter pylori epithelial cell response genes. Infect Immun 2001;69:6970-6980.
47. Naef M, Yokoyama M, Friess H, Büchler MW, Korc M: Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer 1996;66:315-321.
48. Murayama Y, Miyagawa J, Shinomura Y, et al: Significance of the association between heparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer. Int J Cancer 2002;98:505-513.
49. Yoshimura T, Tomita T, Dixon MF, Axon AT, Robinson PA, Crabtree JE: ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa. J Infect Dis 2002;185:332-340.
50. Higashi H, Tsutsumi R, Muto S, et al: SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002;295:683-686.
51. Higashi H, Tsutsumi R, Fujita A, et al: Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci USA 2002;99:14428-14433.
52. Churin Y, Kardalinou E, Meyer TF, Naumann M: Pathogenicity island-dependent activation of Rho GTPases Rac1 and Cdc42 in Helicobacter pylori infection. Mol Microbiol 2001;40:815-823.
53. Nobes CD, Hall A: Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 1999;144:1235-1244.
54. Sung JJ, Leung WK, Go MY, et al: Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000;157:729-735.
55. Fu S, Ramanujam KS, Wong A, et al: Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999;116:1319-1329.
56. Eberhart CE, Dubois RN: Eicosanoids and the gastrointestinal tract. Gastroenterology 1995;109:285-301.
57. Juttner S, Cramer T, Wessier S, et al: Helicobacter pylori stimulates host cyclooxygenase-2 gene transcription: Critical importance of MEK/ERK-dependent activation of USF1/-2 and CREB transcription factors. Cell Microbiol 2003;5:821-834.
58. Sawaoka H, Kawano S, Tsuji S, et al: Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins Leukot Essent Fatty Acids 1998;59:313-316.
59. McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM: Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol 1999;94:1218-1223.
60. 2 in epithelial cells. J Biol Chem 2001;276:804-810.
61. Hirata Y, Maeda S, Mitsuno Y, et al: Helicobacter pylori activates the cyclin D1 gene through mitogen-activated protein kinase pathway in gastric cancer cells. Infect Immun 2001;69:3965-3971.
62. Miehlke S, Yu J, Ebert M, et al: Expression of G1 phase cyclins in human gastric cancer and gastric mucosa of first-degree relatives. Dig Dis Sci 2002;47:1248-1256.
63. kip1. Infect Immun 2000;68:5321-5328.
64. Yu J, Leung WK, Ng EK, et al: Effect of Helicobacter pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia. Aliment Pharmacol Ther 2001;15:1505-1511.
65. Peek RM Jr, Blaser MJ, Mays DJ, et al: Helicobacter pylori strain-specific genotypes and modulation of the gastric epithelial cell cycle. Cancer Res 1999;59:6124-6131.
66. Satoh K, Mutoh H, Eda A, et al: Aberrant expression of CDX2 in the gastric mucosa with and without intestinal metaplasia: Effect of eradication of Helicobacter pylori. Helicobacter 2002;7:192-198.
67. Le'Negrate G, Ricci V, Hofman V, Mograbi B, Hofman P, Rossi B: Epithelial intestinal cell apoptosis induced by Helicobacter pylori depends on expression of the cag pathogenicity island phenotype. Infect Immun 2001;69:5001-5009.
68. Gupta RA, Polk DB, Krishna U, et al: Activation of peroxisome proliferator-activated receptor-γ suppresses nuclear factor κB-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem 2001;276:31059-31066.
69. Rokkas T, Ladas S, Liatsos C, et al: Relationship of Helicobacter pylori CagA status to gastric cell proliferation and apoptosis. Dig Dis Sci 1999;44:487-493.
70. Yu J, Leung WK, Go MY, et al: Relationship between Helicobacter pylori babA2 status with gastric epithelial cell turnover and premalignant gastric lesions. Gut 2002;51:480-484.
71. Uemura N, Okamoto S, Yamamoto S, et al: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
72. Meining A, Bayerdorffer E, Muller P, et al: Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch 1998;432:311-314.
73. Hojo M, Miwa H, Ohkusa T, Ohkura R, Kurosawa A, Sato N: Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16:1923-1932.
74. Correa P, Fontham ET, Bravo JC, et al: Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-1888.
75. Ley C, Mohar A, Guarner J, et al: Helicobacter pylori eradication and gastric preneoplastic conditions: A randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 2004;13:4-10.
76. Leung WK, Lin SR, Ching JY, et al: Factors predicting progression of gastric intestinal metaplasia: Results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-1249.
77. Correa P: Is gastric cancer preventable? Gut 2004;53:1217-1219.
78. Wong BC, Lam SK, Wong WM, et al: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004;291:187-194.